Zejula Tablet, Film Coated
Product Images NDC 0173-0909

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zejula (NDC 0173-0909). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure (Zejula Tab Spl Graphic 01)

Chemical structure of niraparib, the active ingredient in ZEJULA. The diagram illustrates the molecular framework including rings, bonds, and functional groups characteristic of the compound.*

FDA Label Image

Figure 1. Progression-free Survival In Patients With Hr-deficient Tumors (intent-to-treat Population, N = 373) (Zejula Tab Spl Graphic 02)

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months since randomization. The chart compares two groups: one treated with niraparib and the other with placebo. The curve for niraparib remains consistently above the placebo, indicating higher progression-free survival probability over a 24-month period. Patient numbers at risk are listed below the time axis for each group at various intervals.*

FDA Label Image

Figure 2. Progression-free Surivival In The Overall Population (intent-to-treat Population, N=733) (Zejula Tab Spl Graphic 03)

A Kaplan-Meier survival curve graph showing progression-free survival probability over time since randomization in months, comparing niraparib and placebo groups. The graph includes data points with crosses and sample size counts below the x-axis at multiple time points up to 24 months.*

FDA Label Image

Figure 3. Progression-free Survival In The Gbrcamut Cohort Based On Irc Assessment (intent-to-treat Population, N = 203) (Zejula Tab Spl Graphic 04)

A Kaplan-Meier curve comparing progression-free survival probability over 24 months between Niraparib and placebo groups. The Y-axis represents progression-free survival probability from 0 to 1, and the X-axis shows time in months from 0 to 24. The Niraparib group shows higher survival probability throughout the period, with patient counts decreasing over time for both groups displayed below the X-axis.*

FDA Label Image

Zejula 100 mg Tablet 30 Count Label (Zejula Tab Spl Graphic 05)

Zejula 100 mg film-coated tablets packaging label from GlaxoSmithKline LLC. The label shows a gray elliptical tablet imprinted with '100'. It indicates prescription use, contains 30 tablets, and includes storage instructions and barcode. The label specifies the active ingredient as niraparib and lists the NDC number 0173-0909-13.*

FDA Label Image

Zejula 200 mg Tablet 30 Count Label (Zejula Tab Spl Graphic 06)

ZEJULA 200 mg tablets label featuring the brand name, generic name niraparib, and dosage strength. The label shows an image of an oval tablet embossed with 200, indicating 200 mg strength. The packaging contains 30 film-coated tablets, is for oral use, and is labeled by GlaxoSmithKline LLC. Storage instructions and warnings about tamper-evident seals are also visible in small text.*

FDA Label Image

Zejula 300 mg Tablet 30 Count Label (Zejula Tab Spl Graphic 07)

The label for ZEJULA (niraparib) tablets shows the 300 mg strength in tablet, film-coated form. It is labeled for oral use and packaged as 30 tablets. The label includes storage instructions, a barcode, and safety warnings about the integrity of the membrane seal. It is manufactured by GlaxoSmithKline LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.